헌팅턴병 : 시장 기회, 역학적 예측, 영향요인, 파이프라인 분석(2020년 상반기)
Huntington´s Disease - Opportunity Assessments, Epidemiological Forecast Market Dynamics and Pipeline Analytics H1 2020
상품코드 : 945743
리서치사 : GervanoRA Data Services LLP
발행일 : 2020년 07월
페이지 정보 : 영문 185 Pages
US $ 1,250 ₩ 1,495,000
PDF (Single User License)
US $ 1,800 ₩ 2,153,000
PDF (Site License)
US $ 2,500 ₩ 2,991,000
PDF (Global License)


한글목차

헌팅턴병은 상염색체 우성 유전성 신경변성질환으로, 일반인구의 7,500명당 1명이 이환하고 있는 것으로 추정되고 있습니다.

세계의 헌팅턴병 치료제 시장을 조사했으며, 질환의 개요, 치료 알고리즘·가이드라인, 이환 상황, 파이프라인 동향, 미충족 요구와 시장 기회, 주요 파이프라인약, 개발의 마일스톤, 승인 전망, 현재·향후 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.

제1장 서론

제2장 개요

제3장 질환의 개요

제4장 헌팅턴병 치료제 : 시장 역학

제5장 파이프라인약 분석

제6장 파이프라인약의 개요·개발 마일스톤

제7장 승인 추정 타임라인

제8장 경쟁 벤치마킹·시장 기회 평가

제9장 현재·향후 경쟁 구도

KSA 20.07.15
영문 목차

영문목차

Huntington's disease (HD) is a relentless neurodegenerative disease that results in profound disability through a triad of motor, cognitive and neuropsychiatric symptoms with very few therapeutic options. It is an Autosomal dominant, neurodegenerative disease that affects an estimated 1 in 7,500 individuals in the general population, making it one of the most common inherited neurodegenerative diseases. Huntington Disease is a result of mutation in Huntingtin (HTT) gene. Mutated HTT gene generates DNA segment known as a CAG trinucleotide repeat. Adult-onset HD, the most common form of the disease, typically manifests around 40 years of age as a broad spectrum of motor, cognitive and psychiatric disorders. It is predominantly characterized by involuntary choreic movements, behavioral changes and cognitive impairment, which are often preceded by psychiatric symptoms. HTT-targeted therapies are promising therapeutic approaches for the treatment of HD. The therapeutic area has been witnessing continuous research for both symptomatic and disease modifying therapies.

The report "Huntington's disease (HD) Pipeline Drugs - Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analytics, 2020" provides a global therapeutic landscape covering all the molecules under development for the treatment of the disease.

Huntington's disease therapeutics pipeline consists of around 87 molecules under development by a total of 82 companies worldwide. For a comprehensive analysis, we have classified the pipeline into segments based on the molecules' Highest Stage of Development, Drug Class, Mechanism of Action, Route of Administration, Geography, Molecule Type, Molecule Target, Treatment Type and Company Type.

The report is built to provide strategically important competitor information, analytics, and insights to formulate effective counter research and development strategies. Report concentrated more on emerging companies with potentially strong product portfolio and recognized significant and varied types of therapeutics under development. And report clearly explains the opportunities of co-development, partnering and investments.

Report helps emerging companies to understand the strong competitor strategies through its key company profiles and SWOT analysis. Elaborated report information assist clients in understanding the current scenarios in drug development and help in develop and design pipeline based in-licensing and out-licensing strategies. Following segments helps clients to understand this report with more clarity.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 01: INTRODUCTION

CHAPTER 02: EXECUTIVE SUMMARY

CHAPTER 03: DISEASE OVERVIEW

CHAPTER 04: MARKET DYNAMICS OF HUNTINGTON'S DISEASE THERAPIES

CHAPTER 05: PIPELINE DRUGS ANALYTICS OF HUNTINGTON'S DISEASE

CHAPTER 06: PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

CHAPTER 07: ESTIMATED APPROVAL TIMELINES OF HUNTINGTON'S DISEASE PIPELINE DRUGS

CHAPTER 08: OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

CHAPTER 09: CURRENT AND FUTURE COMPETITIVE LANDSCAPE

(주)글로벌인포메이션 02-2025-2992 koreainfo@gii.co.jp
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기